No Data
Ningbo Menovo Pharmaceutical (603538.SH) participated in the selection of Jiangsu Alliance for the fourth and fifth batches of national organized pharmaceutical centralized procurement.
ningbo menovo pharmaceutical (603538.SH) announced that recently, the official website of Jiangsu Provincial Medical Security Bureau released "The 4th-5th batch of national...
Earnings Troubles May Signal Larger Issues for Ningbo Menovo Pharmaceutical (SHSE:603538) Shareholders
Ningbo Menova Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
ningbo menovo pharmaceutical (603538.SH) released its performance for the first three quarters, with a net income of 63.2504 million yuan, a year-on-year increase of 15.97%.
Ningbo Menovo Pharmaceutical (603538.SH) released the third quarter report for 2024, with revenue for the first three quarters at 9.4...
ningbo menovo pharmaceutical (603538.SH): The net income for the first three quarters was 63.2504 million yuan, an increase of 15.97% year-on-year.
On October 29, Glon Hui announced that ningbo menovo pharmaceutical (603538.SH) achieved revenue of 0.949 billion yuan in the first three quarters of 2024, an increase of 2.21% year-on-year; net income attributable to shareholders of the listed company was 63.2504 million yuan, an increase of 15.97% year-on-year; basic earnings per share were 0.29 yuan.
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Ningbo Menovo Pharmaceutical Co., Ltd.'s (SHSE:603538) Price Is Right But Growth Is LackingNo Data
No Data
